Q1 Earnings Forecast for Omnicell Issued By Zacks Research

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research issued their Q1 2025 earnings per share estimates for shares of Omnicell in a note issued to investors on Tuesday, February 25th. Zacks Research analyst R. Department anticipates that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at $0.31 EPS, Q4 2025 earnings at $0.44 EPS, FY2025 earnings at $0.95 EPS, Q1 2026 earnings at $0.19 EPS, Q2 2026 earnings at $0.29 EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at $0.38 EPS and FY2026 earnings at $1.16 EPS.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%.

A number of other research analysts also recently issued reports on the stock. Wells Fargo & Company decreased their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Bank of America decreased their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co. raised their target price on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Barclays lifted their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $52.33.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $39.73 on Thursday. The company has a 50 day simple moving average of $42.65 and a two-hundred day simple moving average of $43.85. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 147.15, a PEG ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after acquiring an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new position in shares of Omnicell during the 4th quarter worth about $37,000. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares during the last quarter. Headlands Technologies LLC purchased a new position in Omnicell in the 4th quarter valued at about $53,000. Finally, First Horizon Advisors Inc. boosted its holdings in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Insider Activity at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.64% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.